Product Description
RLS103, a dry powder inhaled cannabidiol (CBD), is a first-in-class drug/device combination product for the acute treatment of social anxiety disorder. (Sourced from: https://www.receptorlife.com/)
Mechanisms of Action: CB Agonist
Novel Mechanism: Yes
Modality: Device
Route of Administration: Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Receptor Life Sciences
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Epilepsy, Reflex|Panic Disorder|Phobia, Social
Phase 0: Panic Disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05678881 |
RC2022-02 | P1 |
Terminated |
Epilepsy, Reflex |
2024-02-23 |
2024-04-03 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05429788 |
RC2022-01 | P1 |
Withdrawn |
Phobia, Social |
2022-11-08 |
2024-04-03 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
ACTRN12621001365853 |
ACTRN12621001365853 | P1 |
Completed |
Panic Disorder |
2022-01-06 |
2024-08-29 |
Treatments |